National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedCaram MEV, Oerline MK, Dusetzina S
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
The authors investigated coping and material measures of the financial hardship of abiraterone and enzalutamide among patients with advanced prostate cancer with Medicare Part D coverage. They found substantial variations in the adherence rate and out-of-pocket payments, with sociodemographic patient and regional factors found to be associated with both aspects.
AHRQ-funded; HS025707.
Citation: Caram MEV, Oerline MK, Dusetzina S .
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Cancer 2020 Dec 1;126(23):5050-59. doi: 10.1002/cncr.33176..
Keywords: Patient Adherence/Compliance, Medicare, Cancer: Prostate Cancer, Cancer, Medication, Healthcare Costs
Shah SC, Canakis A, Peek RM
Endoscopy for gastric cancer screening is cost effective for Asian Americans in the United States.
Endoscopic screening for gastric cancer is routine in some countries with high incidence and is associated with reduced gastric cancer-related mortality. Immigrants from countries of high incidence to low incidence of gastric cancer retain their elevated risk, but no screening recommendations have been made for these groups in the United States. In this study the investigators aimed to determine the cost effectiveness of different endoscopic screening strategies for noncardia gastric cancer, compared with no screening, among Chinese, Filipino, Southeast Asian, Vietnamese, Korean, and Japanese Americans.
AHRQ-funded; HS026395.
Citation: Shah SC, Canakis A, Peek RM .
Endoscopy for gastric cancer screening is cost effective for Asian Americans in the United States.
Clin Gastroenterol Hepatol 2020 Dec;18(13):3026-39. doi: 10.1016/j.cgh.2020.07.031..
Keywords: Cancer, Digestive Disease and Health, Screening, Racial and Ethnic Minorities, Healthcare Costs
Fiala MA, Gettinger T, Wallace CL
Cost differential associated with hospice use among older patients with multiple myeloma.
Hospice is an effective end-of-life care approach for patients with incurable illnesses such as multiple myeloma; however, it has been historically underutilized. In addition to improving quality of life, hospice enrollment reduces healthcare spending in many incurable illnesses but this has been unstudied in the myeloma population to date. This study examined the cost differential associated with hospice use among older patients with multiple myeloma.
AHRQ-funded; R24 HS019455.
Citation: Fiala MA, Gettinger T, Wallace CL .
Cost differential associated with hospice use among older patients with multiple myeloma.
J Geriatr Oncol 2020 Jan;11(1):88-92. doi: 10.1016/j.jgo.2019.06.010..
Keywords: Elderly, Palliative Care, Cancer, Healthcare Costs
Mitchell AP, Kinlaw AC, Peacock-Hinton S
Use of high-cost cancer treatments in academic and nonacademic practice.
This study compared the use of high-cost cancer drugs at National Cancer Institute (NCI)-designated Comprehensive Cancer Centers with use at non-NCI settings. This cohort study linked cancer registry, administrative, and demographic data for newly diagnosed cancer patients in North Carolina from 2004-2011. The authors selected cancers that use drugs with large differences in reimbursement between higher-priced and lower-priced options (stage IV colorectal, stage IV lung, and stage II-IV head-and-neck cancers). Of 800 eligible patients in the cohort, 79.6% were treated in non-NCI settings. Patients in those settings were more likely to receive high-cost treatment than those treated in NCI settings (36.0% vs. 23.2%). Even after controlling for potential confounding factors, non-NCI patients remained more likely to receive high-cost treatment.
AHRQ-funded; HS000032.
Citation: Mitchell AP, Kinlaw AC, Peacock-Hinton S .
Use of high-cost cancer treatments in academic and nonacademic practice.
Oncologist 2020 Jan;25(1):46-54. doi: 10.1634/theoncologist.2019-0338..
Keywords: Cancer, Healthcare Costs